Michael Schmitz
Stock Analyst at Guggenheim
(2.87)
# 1,758
Out of 5,090 analysts
11
Total ratings
87.5%
Success rate
18.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Buy | $3 → $5 | $3.27 | +52.91% | 1 | Nov 14, 2025 | |
| MRSN Mersana Therapeutics | Downgrades: Neutral | n/a | $27.78 | - | 1 | Nov 14, 2025 | |
| MRUS Merus | Downgrades: Neutral | $109 → $97 | $96.14 | +0.89% | 3 | Sep 30, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $31.74 | +35.48% | 1 | Sep 24, 2025 | |
| EXEL Exelixis | Reiterates: Buy | $45 | $44.36 | +1.44% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $79.64 | +2.96% | 2 | Oct 28, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $12.79 | +212.74% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.08 | - | 1 | Jan 3, 2023 |
Erasca
Nov 14, 2025
Maintains: Buy
Price Target: $3 → $5
Current: $3.27
Upside: +52.91%
Mersana Therapeutics
Nov 14, 2025
Downgrades: Neutral
Price Target: n/a
Current: $27.78
Upside: -
Merus
Sep 30, 2025
Downgrades: Neutral
Price Target: $109 → $97
Current: $96.14
Upside: +0.89%
Genmab
Sep 24, 2025
Upgrades: Buy
Price Target: $43
Current: $31.74
Upside: +35.48%
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $44.36
Upside: +1.44%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $79.64
Upside: +2.96%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $12.79
Upside: +212.74%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.08
Upside: -